CY2237B1 - Substituted pyrazolyl benzenesulfonamides for the - Google Patents

Substituted pyrazolyl benzenesulfonamides for the

Info

Publication number
CY2237B1
CY2237B1 CY0100013A CY0100013A CY2237B1 CY 2237 B1 CY2237 B1 CY 2237B1 CY 0100013 A CY0100013 A CY 0100013A CY 0100013 A CY0100013 A CY 0100013A CY 2237 B1 CY2237 B1 CY 2237B1
Authority
CY
Cyprus
Prior art keywords
substituted pyrazolyl
pyrazolyl benzenesulfonamides
benzenesulfonamides
compounds
inflammation
Prior art date
Application number
CY0100013A
Other languages
English (en)
Inventor
John J Talley
Thomas D Penning
Paul W Collins
Donald J Rogier Jr
James W Malecha
Julie M Miyashiro
Stephen R Bertenshaw
Ish K Khanna
Matthew J Granets
Roland S Rogers
Jeffery S Carter
Stephen H Docter
Stella S Yu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26857022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2237(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/160,594 external-priority patent/US5466823A/en
Application filed by Searle & Co filed Critical Searle & Co
Publication of CY2237B1 publication Critical patent/CY2237B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY0100013A 1993-11-30 2001-06-21 Substituted pyrazolyl benzenesulfonamides for the CY2237B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,594 US5466823A (en) 1993-11-30 1993-11-30 Substituted pyrazolyl benzenesulfonamides
US08/223,629 US5521207A (en) 1993-11-30 1994-04-06 Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation

Publications (1)

Publication Number Publication Date
CY2237B1 true CY2237B1 (en) 2003-07-04

Family

ID=26857022

Family Applications (2)

Application Number Title Priority Date Filing Date
CY0100013A CY2237B1 (en) 1993-11-30 2001-06-21 Substituted pyrazolyl benzenesulfonamides for the
CY200900003C CY2009003I1 (el) 1993-11-30 2009-03-09 Υποκατεστημενα πυραζολυλοβενζολοσουλφοναμιδια για τη θεραπευτικη αγωγη της φλεγμονης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY200900003C CY2009003I1 (el) 1993-11-30 2009-03-09 Υποκατεστημενα πυραζολυλοβενζολοσουλφοναμιδια για τη θεραπευτικη αγωγη της φλεγμονης

Country Status (25)

Country Link
US (2) US5760068A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0731795B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JP3025017B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100263817B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (4) CN1268614C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (4) ATE212985T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (4) CA2177576C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY2237B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ294630B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (6) DE69422306T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK0924201T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (4) ES2172959T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI115053B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR09C0007I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3032696T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU223824B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (2) LU90698I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300024I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306460B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (3) NZ276885A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL180717B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (3) PT923933E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO118291B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2139281C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995015316A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716991B1 (en) 1993-11-30 2004-04-06 G. D. Searle & Co. Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
AU3815495A (en) * 1994-11-08 1996-05-31 Eisai Co. Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
RU2251543C2 (ru) * 1995-05-25 2005-05-10 Джи.Ди.Сирл энд Ко. Дикетон в качестве промежуточного продукта при получении 3-галоген-1н-пиразолов
EP0828718A1 (en) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996041645A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
JP2000510816A (ja) * 1995-10-17 2000-08-22 ジー.ディー.サール アンド カンパニー シクロオキシゲナーゼ−2の検出法
PT880363E (pt) 1996-02-13 2002-12-31 Searle & Co Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4
JP2000504723A (ja) 1996-02-13 2000-04-18 ジー.ディー.サール アンド カンパニー シクロオキシゲナーゼ―2阻害剤および5―リポキシゲナーゼ阻害剤投与の免疫抑制効果
DE69733338T2 (de) 1996-02-13 2006-03-16 G.D. Searle & Co., Chicago Zubereitungen, enthaltend einen cyclooxygenase-2-inhibitor und einen leukotrien-b4-rezeptor-antagonisten
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
ATE408607T1 (de) 1996-04-12 2008-10-15 Searle Llc Substituierte benzensulfonamid-derivate als wirkstoff-vorläufer von cox-2 inhibitoren
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
DK0932402T3 (da) * 1996-10-15 2004-11-08 Searle Llc Metode til anvendelse af cyclooxygenase-2-inhibitorer ved behandling og forebyggelse af neoplasi
IT1287174B1 (it) * 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
CZ176899A3 (cs) * 1996-11-19 1999-10-13 G. D. Searle & Co. Použití inhibitorů cyklooxygenázy-2 jako antiangiogenních látek
DE69808607T2 (de) * 1997-04-03 2003-06-26 G.D. Searle & Co., Chicago Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
EP0979077A1 (en) * 1997-04-18 2000-02-16 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
AUPO941497A0 (en) * 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
AU750356B2 (en) * 1997-09-24 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. 1,5-diphenylpyrazole derivatives
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
WO1999051580A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
ATE284691T1 (de) * 1998-11-02 2005-01-15 Merck & Co Inc Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
WO2000066562A1 (en) * 1999-05-03 2000-11-09 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
CO5261541A1 (es) * 1999-05-14 2003-03-31 Pfizer Prod Inc Terapia de combinacion para el tratamiento de la migrana
CA2373931A1 (en) * 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
ES2200787T3 (es) 1999-12-03 2004-03-16 Pfizer Products Inc. Derivados de acetileno como agentes antiinflamatorios/analgesicos.
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
BR0016031A (pt) 1999-12-03 2002-07-23 Pfizer Prod Inc Derivados de heterociclo-alquilsulfonil pirazol como agentes antiinflamatórios/analgésicos
PT1104759E (pt) 1999-12-03 2004-01-30 Pfizer Prod Inc Compostos heteroaril-fenil-pirazole como agentes anti-inflamatorios e analgesicos
OA11831A (en) * 1999-12-08 2005-08-23 Pharmacia Corp Polymorphic crystalline forms of celecoxib.
US6964978B2 (en) * 1999-12-08 2005-11-15 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
EA008242B1 (ru) * 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
NZ519781A (en) 1999-12-23 2004-04-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20030158245A1 (en) * 2000-03-31 2003-08-21 Tsuneo Yasuma Fused heterocyclic derivatives, their production and use
US20020183362A1 (en) * 2000-04-25 2002-12-05 Pharmacia Corporation 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation
US6403629B2 (en) * 2000-05-02 2002-06-11 J.B. Chemical And Pharmaceuticals Limited Heterocyclic compounds for therapeutic use
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
DK1296665T3 (da) * 2000-06-13 2011-07-18 Wyeth Llc Analgetiske og antiinflammatoriske sammensætninger indeholdende celecoxib og ibuprofen
TR200001872A2 (tr) * 2000-06-26 2002-01-21 Fako �La�Lari A.� 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine ilişkin yöntem.
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2002007721A2 (en) 2000-07-20 2002-01-31 Lauras As Use of cox-2 inhibitors for preventing immunodeficiency
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
AU2002229086A1 (en) * 2000-12-15 2002-06-24 Pharmacia Corporation Selective cox-2 inhibition from non-edible plant extracts
WO2002047706A2 (en) * 2000-12-15 2002-06-20 Pharmacia Corporation Selective cox-2 inhibition from plant extracts
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2435350A1 (en) * 2001-02-02 2002-08-15 Pharmacia Corporation Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
ES2174757B1 (es) * 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
GB0112810D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112802D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
ATE298749T1 (de) 2001-07-05 2005-07-15 Pfizer Prod Inc Heterocyclo-alkylsulfonyl pyrazole als entzündungshemmende/analgetische mittel
DE10135027A1 (de) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0119477D0 (en) * 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
JP2005501083A (ja) * 2001-08-10 2005-01-13 ファルマシア・コーポレーション 炭酸脱水酵素阻害剤
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US6956052B2 (en) * 2001-09-19 2005-10-18 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
PE20030547A1 (es) * 2001-09-24 2003-08-18 Bayer Corp Derivados de imidazol para el tratamiento de la obesidad
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
US20040126438A1 (en) * 2001-12-13 2004-07-01 Obukowicz Mark G. Selective cox-2 inhibition from plant extracts
US20040062823A1 (en) * 2001-12-13 2004-04-01 Obukowicz Mark G. Selective cox-2 inhibition from non-edible plant extracts
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
TW562937B (en) * 2002-03-26 2003-11-21 Nanya Technology Corp Method for fast determining defect type of word line
US7026346B2 (en) * 2002-04-08 2006-04-11 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells
CA2482510A1 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Monotherapy for the treatment of parkinson`s disease with cyclooxygenase-2 (cox 2) inhibitor(s)
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
MXPA04010952A (es) * 2002-05-09 2005-01-25 Pharmacia Corp Compuestos de pirazolilo sustituidos para el tratamiento de la inflamacion.
CN100348586C (zh) * 2002-05-24 2007-11-14 法玛西雅公司 二芳基吡唑的合成方法
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
EP1534683A4 (en) * 2002-06-27 2005-08-24 Nitromed Inc CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHOD OF USE
JP2005535642A (ja) * 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
ES2263058T3 (es) * 2002-08-19 2006-12-01 Glaxo Group Limited Derivados de pirimidina como inhibidores selectivos de cox-2.
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
AU2003267231A1 (en) * 2002-09-20 2004-04-08 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
GB0227443D0 (en) * 2002-11-25 2002-12-31 Glaxo Group Ltd Pyrimidine derivatives
US20060148877A1 (en) * 2002-11-26 2006-07-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
DK1572173T3 (da) 2002-12-13 2010-06-14 Warner Lambert Co Alpha-2-delta-ligand til behandling af symptomer i den nedre urinvej
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004069029A2 (en) * 2003-01-29 2004-08-19 Children's Medical Center Corporation Prevention of surgical adhesions using selective cox-2 inhibitors
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20060142368A1 (en) * 2003-04-08 2006-06-29 Ching-Shih Chen Compounds and methods for inducing apoptosis in proliferating cells
CA2519189C (en) * 2003-05-07 2012-07-17 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
DK2266584T3 (da) * 2003-05-07 2013-01-02 Osteologix As Sammensætning med strontium og D-vitamin til profylakse og/eller behandling af brusk- og knogletilstande
CN1309717C (zh) * 2003-06-03 2007-04-11 李小虎 4-芳基-5h-噻吩-2-酮衍生物、其制法和用途
GB0319037D0 (en) * 2003-08-13 2003-09-17 Glaxo Group Ltd 7-Azaindole Derivatives
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
SI1696907T1 (sl) * 2003-10-03 2013-12-31 The Ohio State University Research Foundation Inhibitorji signaliziranja PDK-1/AKT
US20060079566A1 (en) * 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
WO2005054204A2 (en) * 2003-11-26 2005-06-16 Synchrony Biosciences, Inc. Pharmaceutical compounds that regenerate in vivo
JPWO2005054181A1 (ja) 2003-12-01 2007-12-06 株式会社リバース・プロテオミクス研究所 抗癌剤の新規標的タンパク質および対応する新規抗癌剤(スプナール)
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
US7070816B2 (en) 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
JP4718453B2 (ja) * 2004-04-12 2011-07-06 武田薬品工業株式会社 Gタンパク質共役型レセプタータンパク質の新規リガンドとその用途
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2585423A1 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
EP1833476A1 (en) 2004-11-23 2007-09-19 PLIVA HRVATSKA d.o.o. Extended release pharmaceutical composition of celecoxib
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US20080200527A1 (en) * 2005-06-17 2008-08-21 Carex Sa Cannabinoid Receptor Modulators
AU2006261841B8 (en) 2005-06-27 2012-12-06 Exelixis Patent Company Llc Pyrazole based LXR modulators
HUP0500730A2 (en) 2005-07-29 2007-02-28 Richter Gedeon Vegyuszeti Gyar 1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
WO2007059311A2 (en) 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
WO2007126609A1 (en) 2006-03-29 2007-11-08 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5399262B2 (ja) 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Lxrおよびfxrのモジュレーター
BRPI0720351A2 (pt) 2006-12-22 2019-05-14 Recordati Ireland Limited terapia de combinação para distúrbios do trato urinário inferior com ligantes a2o e aines.
FR2911136B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
CN101679244B (zh) * 2007-04-11 2014-01-01 橘生药品工业株式会社 5元杂环衍生物及其医药用途
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
US20090062364A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched celecoxib
WO2009152647A1 (zh) 2008-06-20 2009-12-23 江苏恩华药业股份有限公司 芳烷基哌啶衍生物及其在制备镇痛、镇静药物中的应用
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
ES2588504T3 (es) 2008-10-22 2016-11-03 Array Biopharma, Inc. Compuestos de pirazolo[1,5-a]pirimidina sustituidos como compuestos intermedios en la síntesis de inhibidores de TRK quinasa
US8785466B2 (en) * 2008-10-31 2014-07-22 Loyola University Chicago Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
US8686017B2 (en) * 2008-10-31 2014-04-01 Loyola University Chicago Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011050944A1 (en) 2009-10-28 2011-05-05 Ratiopharm Gmbh Formulations containing celecoxib
WO2011055233A2 (en) 2009-11-03 2011-05-12 Actavis Group Ptc Ehf Improved process for preparing celecoxib polymorph
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
SG10201506593XA (en) 2010-05-20 2015-10-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
EP2635274B1 (en) 2010-11-01 2017-12-06 The Ohio State University Research Foundation Anti-staphylococcal celecoxib derivatives
CN102746231A (zh) * 2011-04-20 2012-10-24 天津药物研究院 塞来昔布制备工艺
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2013187965A1 (en) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
CN102746232A (zh) * 2012-07-03 2012-10-24 石药集团中诺药业(石家庄)有限公司 一种塞来昔布杂质的制备方法
WO2014012074A2 (en) * 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
US9044464B2 (en) 2012-07-12 2015-06-02 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
WO2014018888A1 (en) 2012-07-26 2014-01-30 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as tak1 inhibitors in disease treatment
JP6352302B2 (ja) 2012-12-28 2018-07-04 ダウ アグロサイエンシィズ エルエルシー 穀類における真菌防除のための相乗性殺真菌性混合物
US9107947B2 (en) 2013-01-31 2015-08-18 The Penn State Research Foundation Anti-cancer compositions and methods
WO2014138616A2 (en) * 2013-03-08 2014-09-12 Translational Drug Development, Llc Pyrazole compounds and methods of use thereof
CA3051327A1 (en) 2013-03-15 2014-09-18 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
US9533984B2 (en) 2013-04-19 2017-01-03 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104974091B (zh) * 2014-04-10 2018-01-02 沈阳药科大学 3‑甲基‑1,5‑二芳基吡唑类化合物及其制备方法和用途
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
CR20170263A (es) 2014-11-16 2017-10-18 Array Biopharma Inc Forma cristalina de sulfato acido de (s)-n- (5- ( (r)-2- (2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]-pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
RU2017126717A (ru) 2014-12-30 2019-01-31 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Применение пиколинамидов в качестве фунгицидов
MX2017008418A (es) 2014-12-30 2017-09-28 Dow Agrosciences Llc Picolinamidas con actividad fungicida.
MX2017008407A (es) 2014-12-30 2017-10-02 Dow Agrosciences Llc Compuestos de picolinamida con actividad fungicida.
AU2015374427C1 (en) 2014-12-30 2018-11-08 Corteva Agriscience Llc Use of picolinamide compounds as fungicides
CA2972403A1 (en) 2014-12-30 2016-07-07 Dow Agrosciences Llc Picolinamide compounds with fungicidal activity
CA2973597A1 (en) 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
WO2016177776A1 (en) 2015-05-04 2016-11-10 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
CN107847437B (zh) 2015-05-28 2024-03-26 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
CN104945388A (zh) * 2015-07-09 2015-09-30 南京大学 4-(3-(3-(4-氯香豆素)-酰腙)-5-苯基-吡唑)苯磺酰胺类衍生物的制备方法及在抗癌药物中的应用
SG11201803438XA (en) 2015-10-26 2018-05-30 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
AU2017218437A1 (en) 2016-02-10 2018-08-23 Cocoon Biotech Inc. Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs silk fibroin and a gelling agent and uses thereof
PT3439662T (pt) 2016-04-04 2024-09-30 Loxo Oncology Inc Formulações líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
LT3800189T (lt) 2016-05-18 2023-10-10 Loxo Oncology, Inc. (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas
AU2017275844A1 (en) 2016-05-27 2019-01-17 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
CA3034211A1 (en) 2016-08-18 2018-02-22 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
EP3509604A4 (en) 2016-09-07 2020-08-26 Trustees of Tufts College POLYTHERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
JP7112429B2 (ja) 2017-05-02 2022-08-03 コルテバ アグリサイエンス エルエルシー 芝草上の真菌疾患に対する殺菌剤としての非環式ピコリンアミド化合物の使用
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN111566095B (zh) 2017-11-03 2024-09-27 阿克拉瑞斯治疗股份有限公司 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
CN112823005B (zh) 2018-08-10 2024-08-20 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
CN111039982A (zh) * 2018-10-12 2020-04-21 南京大学 一类含新型磷脂胺骨架的吡唑磺胺衍生物的设计、合成
KR20210076072A (ko) 2018-10-15 2021-06-23 코르테바 애그리사이언스 엘엘씨 옥시피콜린아미드의 합성 방법
US11739078B2 (en) 2019-02-22 2023-08-29 Insilico Medicine Ip Limited Methods of inhibiting kinases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3962897A4 (en) 2019-05-02 2022-12-14 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114554848A (zh) 2019-10-18 2022-05-27 科迪华农业科技有限责任公司 用于合成吡啶酰胺的方法
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4267132A1 (en) 2020-12-28 2023-11-01 Dr. Reddy's Laboratories Ltd. Celecoxib for treating pain
WO2022149937A2 (ko) 2021-01-08 2022-07-14 서울대학교 산학협력단 골관절염 치료를 위한 건조된 세포 분비물 기반 치료제
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN114292235B (zh) * 2021-12-29 2023-04-14 江苏天和制药有限公司 一种地拉考昔的制备和提纯方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
DE2536003C2 (de) * 1975-08-08 1985-11-14 Schering AG, 1000 Berlin und 4709 Bergkamen Pyrazol-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Derivate
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
GB8814587D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5387693A (en) * 1991-08-08 1995-02-07 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole intermediate compounds
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
ES2102195T3 (es) * 1992-12-28 1997-07-16 Eisai Co Ltd Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides

Also Published As

Publication number Publication date
HK1021935A1 (en) 2000-07-21
PL314695A1 (en) 1996-09-16
KR100229343B1 (ko) 1999-11-01
JP3445762B2 (ja) 2003-09-08
CN1141630A (zh) 1997-01-29
CN1495170A (zh) 2004-05-12
LU91538I2 (fr) 2009-05-06
CZ150396A3 (en) 1996-12-11
FI962249A7 (fi) 1996-05-29
AU1171495A (en) 1995-06-19
DE69422306D1 (de) 2000-01-27
ES2172959T3 (es) 2002-10-01
DE69429836D1 (de) 2002-03-21
CN1127484C (zh) 2003-11-12
CA2177576C (en) 1999-10-26
ATE212985T1 (de) 2002-02-15
JPH09506350A (ja) 1997-06-24
NL300024I2 (nl) 2001-04-02
FI962249A0 (fi) 1996-05-29
DE69422306T2 (de) 2000-05-18
NO962184D0 (no) 1996-05-29
DE69429836T2 (de) 2002-07-18
HU223824B1 (hu) 2005-02-28
CA2276946A1 (en) 1995-06-08
ATE187965T1 (de) 2000-01-15
CY2009003I2 (el) 2009-11-04
HUT74180A (en) 1996-11-28
FI115053B (fi) 2005-02-28
KR100263817B1 (ko) 2000-08-16
RO118291B1 (ro) 2003-04-30
NZ336428A (en) 2005-02-25
PT924201E (pt) 2002-06-28
NO962184L (no) 1996-05-29
PT923933E (pt) 2002-10-31
WO1995015316A1 (en) 1995-06-08
DE69422306T4 (de) 2000-09-07
CN1268614C (zh) 2006-08-09
EP0731795A1 (en) 1996-09-18
CZ294630B6 (cs) 2005-02-16
NO306460B1 (no) 1999-11-08
RU2139281C1 (ru) 1999-10-10
DK0924201T3 (da) 2002-05-21
ES2141916T3 (es) 2000-04-01
CA2276945A1 (en) 1995-06-08
ATE219937T1 (de) 2002-07-15
NZ276885A (en) 1999-08-30
FR09C0007I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-12-31
CY2009003I1 (el) 2009-11-04
ES2193609T3 (es) 2003-11-01
US5753688A (en) 1998-05-19
HK1013649A1 (en) 1999-09-03
KR100261669B1 (en) 2000-07-15
CA2276945C (en) 2006-08-01
DK0731795T3 (da) 2000-05-15
CN1134418C (zh) 2004-01-14
LU90698I2 (fr) 2001-02-13
CA2177576A1 (en) 1995-06-08
ATE233245T1 (de) 2003-03-15
JP3921451B2 (ja) 2007-05-30
CA2277954A1 (en) 1995-06-08
NZ536355A (en) 2006-08-31
JP3025017B2 (ja) 2000-03-27
FR09C0007I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-04-17
ES2180233T3 (es) 2003-02-01
DE10075033I1 (de) 2001-01-18
DK0923933T3 (da) 2002-10-21
GR3032696T3 (en) 2000-06-30
CN1280126A (zh) 2001-01-17
DE69432193T2 (de) 2004-01-15
PT731795E (pt) 2000-05-31
EP0731795B1 (en) 1999-12-22
AU690609B2 (en) 1998-04-30
JP2000109466A (ja) 2000-04-18
CN1061036C (zh) 2001-01-24
CN1280125A (zh) 2001-01-17
NL300024I1 (nl) 2001-01-02
US5760068A (en) 1998-06-02
DE10075033I2 (de) 2001-08-02
HU9601455D0 (en) 1996-07-29
JP2003238536A (ja) 2003-08-27
DE69430930D1 (de) 2002-08-08
DE69432193D1 (de) 2003-04-03
DE69430930T2 (de) 2003-02-20
PL180717B1 (pl) 2001-03-30

Similar Documents

Publication Publication Date Title
CY2237B1 (en) Substituted pyrazolyl benzenesulfonamides for the
AU3202595A (en) 1,2-substituted imidazolyl compounds for the treatment of inflammation
AU4284196A (en) Substituted biphenyl compounds for the treatment of inflammation
AU6027694A (en) Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
AU8599091A (en) Antimicrobial agents as well as substituted 2-cyclohexan-1-y1-amine derivatives and their preparation
ES8608535A1 (es) Procedimiento para preparar una composicion para el tratamiento topico de acne
ES8102561A1 (es) Procedimiento de preparacion de los aril-1 arilsulfonil-4 a amino-propoxi-3 1h pirazoles
AU7675896A (en) Sulfur containing di-tert-butylphenol compounds useful as anti-inflammatory agents
HUT74710A (en) Herbicidal pyrrolopyridine compounds, compositions containing them and use thereof
ZA9410280B (en) 4-arylisoindole analgesic
AU7610194A (en) Thiocarbamoyl compounds used as antimicrobial agents